Corrigendum to “DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer” [Canc. Lett. 501 224–233] (Cancer Letters (2021) 501 (224–233), (S0304383520306030), (10.1016/j.canlet.2020.11.011))

Dotan Moskovich, Adi Alfandari, Yael Finkelshtein, Avivit Weisz, Aviva Katzav, Debora Kidron, Evgeny Edelstein, Daniel Veroslavski, Ruth Perets, Nissim Arbib, Yfat Kadan, Ami Fishman, Bernard Lerer, Martin Ellis, Osnat Ashur-Fabian*

*Corresponding author for this work

Research output: Contribution to journal › Comment/debate

Fingerprint

Dive into the research topics of 'Corrigendum to “DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer” [Canc. Lett. 501 224–233] (Cancer Letters (2021) 501 (224–233), (S0304383520306030), (10.1016/j.canlet.2020.11.011))'. Together they form a unique fingerprint.

Medicine & Life Sciences